We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis has released new data from a late-stage study showing that its multiple sclerosis (MS) drug Kesimpta (ofatumumab) reduced the risk of disease progression. Read More
Merck has decided to end research and development on MK-7110, an experimental oral drug for treatment of hospitalized coronavirus patients that had shown promise in a late-stage trial. Read More
People vaccinated with Pfizer/BioNTech’s double-dose COVID-19 vaccine will likely need to receive a booster shot within a year of full inoculation, as well as an annual shot, according to Pfizer CEO Albert Bourla. Read More
Those treated with the antibody combination who suffered from symptomatic infection generally saw their symptoms end in one week vs. three weeks. Read More
Patients already participating in the study will continue to be assessed, the company said, adding it is developing an experimental inhaled formulation of the antiviral. Read More
New data from Moderna’s phase 3 COVID-19 vaccine trial have shown that the U.S. drugmaker’s two-dose inoculation remains highly effective against the virus six months after the second shot, including for severe infection, the company said Tuesday. Read More
More harmful side effects were found in clinical study reports submitted to regulators than in listings about the same medicines in trial registries or published studies. Read More
Regeneron Pharmaceuticals has said its COVID-19 antibody cocktail, REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic infections by 81 percent in a late-stage trial. Read More
Patients given the JAK inhibitor were only 2.7 percent less likely than those who received standard of care to progress to ventilation or death. Read More